Zilovertamab
- Generic Name
- Zilovertamab
- Drug Type
- Biotech
- CAS Number
- 2485779-13-1
- Unique Ingredient Identifier
- FEH7RQ7B3J
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Withdrawn
- Conditions
- Lymphatic DiseasesImmunoproliferative DisordersLymphoma, Mantle-CellImmune System DiseasesLymphoma, Non-HodgkinLymphomaLymphoproliferative DisordersLymphoma, B-Cell
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Registration Number
- NCT05431179
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 6
- Registration Number
- NCT05156905
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Phase 2
Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 5
- Registration Number
- NCT04501939
- Locations
- 🇺🇸
UCSD Koman Family Outpatient Pavilion, San Diego, California, United States
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Phase 1
Completed
- Conditions
- B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Target Recruit Count
- 95
- Registration Number
- NCT03088878
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sanford Stem Cell Clinical Center at UCSD, La Jolla, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 3
- Registration Number
- NCT02860676
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Barbara Parker, MD
- Target Recruit Count
- 22
- Registration Number
- NCT02776917
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Thomas Kipps
- Target Recruit Count
- 26
- Registration Number
- NCT02222688
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath